Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
49
days
Bayesian‐Estimated Vancomycin AUC24 as a Near‐Term Renal Risk Signal after Therapeutic Drug Monitoring: A Multicenter Cohort Study
AuthorsTran Van Anh; Bui Thi Tham; Tran Thi Ngan; Nguyen Duc Long,; Nguyen Huong Giang; Nguyen Hoang Anh; Vu Dinh Hoa; Hoang Van Dung; Nguyen Thi Thu Phuong
Affiliations1. Faculty of Pharmacy Hai Phong University of Medicine and Pharmacy Hai Phong Viet Nam; 2. Department of Pharmacy Hai Phong International Hospital Hai Phong Viet Nam; 3. Hanoi University of Pharmacy Hanoi Viet Nam; 4. Vietnam National Drug Information and Adverse Drug Reaction Monitoring Centre Hanoi Viet Nam; 5. Department of Internal Medicine Hai Phong International Hospital Hai Phong Viet Nam; 6. Department of Internal Medicine Hai Phong University of Medicine and Pharmacy Hai Phong Viet Nam
59
days
Tamoxifen Therapy Is Associated With Altered Intestinal P‐Glycoprotein Activity In Vivo
AuthorsÁlef Machado Gomes Pego; Fernanda de Lima Moreira; Ana Flavia Mendes Batista; Adriana Rocha; Maria Paula Marques Pereira; Eduardo Barbosa Coelho; Jurandyr Moreira de Andrade; Geraldo Duarte; Vera Lucia Lanchote; João Paulo Bianchi Ximenez
Affiliations1. School of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo Ribeirão Preto São Paulo Brazil; 2. Faculty of Pharmacy Federal University of Rio de Janeiro Rio de Janeiro Rio de Janeiro Brazil; 3. Ribeirão Preto Medical School University of São Paulo Ribeirão Preto São Paulo Brazil
69
days
PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD)
AuthorsYuwen Jin; Junjie Ding; Xiaohan Hua; Wei Duan; Mo Chen; Zhaohui Zhou; Ramesh V Pandherpur; Jin Dong; Sharma Pradeep; Peiming Ma; Weifeng Tang; Diansong Zhou
Affiliations1. Clinical Pharmacology R&D China AstraZeneca Shanghai China; 2. Respiratory & Immunology R&D China AstraZeneca Shanghai China; 3. Biometrics and Data Science R&D China AstraZeneca Shanghai China; 4. Clinical Safety R&D China AstraZeneca Shanghai China; 5. Clinical Development BioPharmaceuticals R&D AstraZeneca Bengaluru India; 6. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Gaithersburg Maryland USA; 7. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Cambridge UK; 8. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Waltham Massachusetts USA
133
days
Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First‐In‐Human Study Using Single and Multiple Ascending Doses
AuthorsNathalie Chauret; Denis Garceau; Laurent Harvey; Zelie Bailes; Elizabeth A. Duncan; Rhian McNaughton; Miren Zamacona
Affiliations1. Bellus Health Laval Quebec Canada; 2. GSK London UK; 3. GSK Durham North Carolina USA
73
days
Population Pharmacokinetics and Exposure–Response Analyses of Vepdegestrant, a First‐in‐Class PROteolysis‐TArgeting Chimera Estrogen Receptor Degrader
AuthorsDerek Z. Yang; Joanna C. Masters; Hechuan Wang; Lana Tran; Yuanyuan Zhang; Kimberly C. Lee; Weiwei Tan; Brian Jermain
Affiliations1. Pfizer Inc San Diego CA USA; 2. Arvinas Operations, Inc. New Haven CT USA; 3. Pfizer Inc Groton CT USA
114
days
FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease
AuthorsPoonam R. Delvadia; Anantha Ram Nookala; Gopichand Gottipati; Sreedharan Sabarinath; Ramana S. Uppoor; Mehul U. Mehta; Xiulian Du; Yow‐Ming C. Wang; Milos Dokmanovic; Riley Myers; Jessica Stevens; Laura Baldassari; Paul Lee; Laura Jawidzik; Sandhya Apparaju; Suna Seo; Nina N. Brahme; Sarah J. Schrieber
Affiliations1. Division of Neuropsychiatric Pharmacology Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 2. Therapeutic Biologics Program Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 3. Division of Product Quality Assessment XIII Office of Product Quality Assessment III Office of Pharmaceutical Quality Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 4. National Institute for Innovation in Manufacturing Biopharmaceuticals University of Delaware Newark DE USA; 5. Division of Neurology II Office of Neuroscience Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 6. Clintrex Research LLC A BlueRidge Life Sciences Company Houston TX USA; 7. Division of Gastroenterology Office of Immunology and Inflammation Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 8. Science Review Staff Office of Therapeutic Biologics and Biosimilars Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA
70
days
From Small Data to Big Decisions: How Clinical Pharmacology Shapes Rare Disease Development
AuthorsYan Xu; Alissa Verone‐Boyle; Natalie Schmitz; Hamim Zahir; Brian A. Willis
Affiliations1. Clinical Pharmacology and Pharmacometrics, Biogen Cambridge MA USA
63
days
Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals
AuthorsParidhi Gupta; Ashish Sharma; Bernd Meibohm
Affiliations1. Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee Health Science Center Memphis TN USA; 2. Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals Ridgefield CT USA
84
days
First‐in‐Human Study of a Long‐Acting GLP‐1 Receptor Agonist (TE‐8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus
AuthorsYa‐Shan Chuang; Jon D. Wright; Mun‐Teng Wong; Kushal J Paneliya; Wei‐Shiung Yang; Hsing‐Mao Chu; Tse Wen Chang; Thomas M Polasek
Affiliations1. Immunwork, Inc. Taipei City Taiwan; 2. CMAX Clinical Research Pty Ltd Adelaide Australia; 3. Department of Internal Medicine National Taiwan University Hospital Taipei City Taiwan; 4. T‐E Meds, Inc. Taipei City Taiwan; 5. Centre for Medicine Use and Safety Monash University Melbourne Australia
203
days
An Open‐Label, 2‐Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects
AuthorsDetlef Albrecht; Elizabeth Hussey; Richard B. Lipton
Affiliations1. Satsuma Pharmaceuticals Inc. Durham NC USA; 2. Allucent Cary NC USA; 3. Albert Einstein College of Medicine and Montefiore Headache Center Bronx NY USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days